We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editor's Correspondence |

The Other Side of the Bezafibrate Infarction Prevention Trial Data—Reply

Alexander Tenenbaum, MD, PhD; Michael Motro, MD; Enrique Z. Fisman, MD; David Tanne, MD; Valentina Boyko, MS; Solomon Behar, MD
Arch Intern Med. 2005;165(20):2432. doi:10.1001/archinte.165.20.2432-a.
Text Size: A A A
Published online


In reply

We thank McCormack and Loewen for their interest and the opportunity to further discuss and clarify our results. They are concerned about a possible “increase in mortality,” particularly from cardiovascular causes, in patients without MS treated with bezafibrate on the basis of their cross-referencing subset analysis of our report1 and the originally published BIP study data.2 However, McCormack and Loewen had overlooked our statement in the “Methods” section that in our report “[t]he follow-up period for mortality registration lasted until March 2000 (mean ± SD, 8.1 ± 0.8 years; range, 4.9-9.7 years).”1(p1155) In contrast, in the originally published BIP study data, the follow-up period lasted until May 1998 (mean ± SD follow-up, 6.2 ± 0.8 years). This point was also clarified in the abstract and emphasized additionally in Figure 2B and its legend. We believe that McCormack and Loewen's erroneous “cross-referencing” comparison of the mortality data from the 2 different reports with the different follow-up periods has lead to a gross miscalculation and consequently to a proposed concluding statement that has no scientific validity. We present the actual mortality data for patients without MS in the Table.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles